Oestrogen therapy for urinary incontinence in post-menopausal women

Cody, June D; Richardson, Karen; Moehrer, Birgit; Hextall, Andrew; Glazener, Cathryn

doi:10.1002/14651858.cd001405.pub2

Cited by 79 publications

(63 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results of these studies were included and confirmed in the Cochrane Database [35] meta-analysis which covered a total of 19,313 incontinent women among whom 9417 were treated by oestrogens, in 33 studies (16 of which addressed specifically SUI). There was no analysis by type of UI.…”

Section: Data Resulting From Secondary Analyses Of Randomised Trials mentioning

confidence: 99%

Menopause, hormone treatment and urinary incontinence at midlife

et al. 2013

View full text Add to dashboard Cite

Section: Data Resulting From Secondary Analyses Of Randomised Trials mentioning

confidence: 99%

Menopause, hormone treatment and urinary incontinence at midlife

et al. 2013

View full text Add to dashboard Cite

“…More recently, both a Cochrane review from 2003 [5] and a study from Fantl et al [6] report improvement of urinary tract infections as well as urge and stress incontinence symptoms from HT when compared to placebo. However, other studies show no improvement [7,8], worsening of preexisting incontinence or even de novo incontinence when HT was introduced [9][10][11][12]. The WHI study found that HT users ran a higher risk of developing stress incontinence (SUI) than mixed (MUI) or urge incontinence (UUI), and that hormonal supplementation with estrogen alone led to a higher risk for developing UI than an estrogen/progestin combination [9].…”

Section: Introductionmentioning

confidence: 99%

Serum estradiol does not differentiate stress, mixed and urge incontinent women around menopause. A report from the Women's Health in the Lund Area (WHILA) study

Hamer

Källén

Lidfeldt

et al. 2011

European Journal of Obstetrics & Gynecology and Reproductiv

View full text Add to dashboard Cite

Serum estradiol does not differentiate stress, mixed and urge incontinent women around menopause. A report from the Women's Health in the Lund Area (WHILA) study.Andrada, Maria; Källén, Karin; Lidfeldt, Jonas; Samsioe, Göran; Teleman, Pia General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.• You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. To outline serum estradiol levels in perimenopausal women with stress, mixed or urge incontinence. We believe the majority of urgency symptoms in perimenopausal women to be caused by a pelvic floor dysfunction and a hypermobility of the bladder neck. If this is the case, there would be no difference in estradiol levels between the groups. Study design:Setting: university hospital. In the observational Women´s Health In the Lund Area study, a subset of 400/2221 women reporting urinary incontinence completed a detailed questionnaire regarding lower urinary tract symptoms and had their serum steroid hormone levels measured.Statistical analyses were made by Chi-square test, nonparametrical tests, ANOVA, multi-and univariate logistic regression analysis. Results:Stress incontinence was reported by 196, mixed incontinence by 153 and urge incontinence by 43 women. Serum estradiol did not differ significantly between stress incontinent (median 49.5 pmo/l, range 2.63-875.4), urge incontinent ( median 31.6 pmol/l, range 2.63-460.7) or mixed incontinent women ( median 35.5 pmol/l, range 2.63-787.9, p = 0.62). Logistic regression analysis correcting for age, parity, hormonal status, smoking, hysterectomy and BMI also failed to show any difference in estradiol levels between the groups (p=0.41-0.58). Conclusion:No significant differences in serum estradiol levels between stress, mixed or urge incontinent perimenopausal women could be demonstrated . 4Keywords:Female urinary incontinence; mixed urinary incontinence; serum estradiol; stress urinary incontinence; urge urinary incontinence.5

show abstract

“…In a randomized trial of 88 symptomatic menopausal women comparing oral hormone therapy, percutaneous gel, and transdermal patch, the best rates of continence were reported in patients who received the estrogen patch (100%) and the percutaneous estrogen gel (90%) [33]. Local hormone therapy (ie, intravaginal creams or tablets) has demonstrated benefit for improvement in incontinence with an acceptable side effect profile [34].…”

Section: Pharmacologic and Hormone Therapymentioning

confidence: 99%

Nonsurgical Interventions for Incontinence: Where Is the Evidence?

Thompson

Kaufman

2010

Curr Bladder Dysfunct Rep

View full text Add to dashboard Cite

Urinary incontinence is a remarkably common urologic condition that results in significant clinical and economic sequelae. Although it is likely underestimated, the overall prevalence of urinary incontinence is projected to be between 15% and 38%. Evaluation frequently can be completed without invasive testing. Conservative therapy for incontinence often employs a multimodal approach that can include behavioral therapy, pelvic floor muscle training, external stimulation, medical devices, and pharmacologic treatment. Herein we present an overview of several conservative treatment options for stress and mixed urinary incontinence and review the available literature regarding these therapies. Despite substantial research into conservative incontinence treatment, few robust studies exist to guide practitioner interventions, and great opportunity exists for future evaluation to advance our knowledge regarding nonsurgical incontinence therapy.

show abstract

Oestrogen therapy for urinary incontinence in post-menopausal women

Cited by 79 publications

References 80 publications

Menopause, hormone treatment and urinary incontinence at midlife

Menopause, hormone treatment and urinary incontinence at midlife

Serum estradiol does not differentiate stress, mixed and urge incontinent women around menopause. A report from the Women's Health in the Lund Area (WHILA) study

Nonsurgical Interventions for Incontinence: Where Is the Evidence?

Contact Info

Product

Resources

About